• Cantargia posted Q1 net sales of SEK 0.5 million, swinging from no revenue a year earlier.
• Operating loss narrowed to SEK 36.9 million from SEK 45 million a year earlier, while the net loss improved to SEK 33 million from SEK 46.9 million.
• Cash and cash equivalents rose to SEK 246 million from SEK 103.9 million a year earlier; short-term investments were SEK 12 million versus none.
• The group highlighted early data from an investigator-initiated Phase Ib/IIa study showing complete remission in all evaluated high-risk MDS patients, prompting a formal hematology development program.
• It also said it is reassessing the timing and structure of its planned Phase IIb/III pancreatic cancer study with nadunolimab to reflect new Phase III data for RAS inhibitors from Revolution Medicines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.